TABLE 1.
Baseline Patient Characteristics for All Patients in the Dose-Escalation and Expansion Phases and Patients with GIST Receiving Ripretinib 150 mg Once Daily
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.